Hernàn Picard

2.8k total citations · 2 hit papers
39 papers, 2.0k citations indexed

About

Hernàn Picard is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Neurology. According to data from OpenAlex, Hernàn Picard has authored 39 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Psychiatry and Mental health, 12 papers in Pathology and Forensic Medicine and 6 papers in Neurology. Recurrent topics in Hernàn Picard's work include Migraine and Headache Studies (25 papers), Trigeminal Neuralgia and Treatments (11 papers) and Psychosomatic Disorders and Their Treatments (8 papers). Hernàn Picard is often cited by papers focused on Migraine and Headache Studies (25 papers), Trigeminal Neuralgia and Treatments (11 papers) and Psychosomatic Disorders and Their Treatments (8 papers). Hernàn Picard collaborates with scholars based in United States, Germany and France. Hernàn Picard's co-authors include Daniel D. Mikol, Robert Lenz, Feng Zhang, Uwe Reuter, Gregor Broessner, Jo Bonner, Peter J. Goadsby, Yngve Hallström, Sandhya Sapra and Messoud Ashina and has published in prestigious journals such as New England Journal of Medicine, Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Hernàn Picard

37 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Controlled Trial of Erenumab for Episodic Migraine

2017 631 citations Peter J. Goadsby, Uwe Reuter et al. profile →
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

2018 423 citations David W. Dodick, Messoud Ashina et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Hernàn Picard	1.6k	1.1k	592	219	176	39	2.0k
Lars Neeb	1.3k 0.8×	667 0.6×	480 0.8×	226 1.0×	66 0.4×	72	1.7k
Samaira Younis	1.1k 0.7×	554 0.5×	338 0.6×	199 0.9×	112 0.6×	32	1.3k
Joe Hirman	1.5k 0.9×	1.1k 1.0×	675 1.1×	134 0.6×	41 0.2×	53	1.8k
Karen L. Hoskin	1.8k 1.1×	1.3k 1.2×	1.0k 1.7×	214 1.0×	72 0.4×	28	2.1k
Agustin Melo‐Carrillo	1.2k 0.7×	618 0.6×	449 0.8×	208 0.9×	60 0.3×	32	1.5k
Shazia Afridi	1.2k 0.8×	841 0.8×	549 0.9×	176 0.8×	149 0.8×	32	1.8k
G.A. Lambert	1.3k 0.8×	860 0.8×	723 1.2×	239 1.1×	124 0.7×	62	2.0k
Vanessa Kainz	1.9k 1.2×	896 0.8×	741 1.3×	424 1.9×	236 1.3×	20	2.5k
F. Michael Cutrer	2.4k 1.5×	1.4k 1.3×	871 1.5×	562 2.6×	338 1.9×	47	3.0k
Mohammad Al‐Mahdi Al‐Karagholi	1.2k 0.7×	571 0.5×	412 0.7×	218 1.0×	58 0.3×	60	1.5k

Countries citing papers authored by Hernàn Picard

Since Specialization

Citations

This map shows the geographic impact of Hernàn Picard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hernàn Picard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hernàn Picard more than expected).

Fields of papers citing papers by Hernàn Picard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hernàn Picard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hernàn Picard. The network helps show where Hernàn Picard may publish in the future.

Co-authorship network of co-authors of Hernàn Picard

This figure shows the co-authorship network connecting the top 25 collaborators of Hernàn Picard. A scholar is included among the top collaborators of Hernàn Picard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hernàn Picard. Hernàn Picard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Merola, Joseph F., Lawrence Charles Parish, Lyn Guenther, et al.. (2023). Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology. 90(3). 485–493. 13 indexed citations

Mease, Philip J., Gülen Hatemi, Maria Paris, et al.. (2023). Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome. American Journal of Clinical Dermatology. 24(5). 809–820. 25 indexed citations

Tepper, Stewart J., Messoud Ashina, Uwe Reuter, et al.. (2021). Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. The Journal of Headache and Pain. 22(1). 81–81. 11 indexed citations

Mikol, Daniel D., et al.. (2020). Migraine Polygenic Risk Score Is Associated with Severity of Migraine – Analysis of Genotypic Data from Four Placebo-controlled Trials of Erenumab (1214). Neurology. 94(15_supplement). 1 indexed citations

Pavlović, Jelena, Koen Paemeleire, Hartmut Göbel, et al.. (2020). Efficacy and safety of erenumab in women with a history of menstrual migraine. The Journal of Headache and Pain. 21(1). 95–95. 30 indexed citations

Reuter, Uwe, Todd J. Schwedt, David Kudrow, et al.. (2019). Long-term efficacy of erenumab in patients with episodic migraine who have failed prior preventive migraine therapies. European Journal of Neurology. 26. 637–637. 2 indexed citations

Vargas, Bert B., Amaal J. Starling, Stephen D. Silberstein, et al.. (2018). Erenumab Immunogenicity: a Pooled Analysis of Phase 2 and Phase 3 Migraine Prevention Clinical Trials (P4.098). Neurology. 90(15_supplement). 5 indexed citations

McAllister, Peter, Lawrence C. Newman, Cristina Tassorelli, et al.. (2018). Efficacy of Erenumab For the Treatment of Patients with Episodic Migraine with Aura (P4.094). Neurology. 90(15_supplement). 3 indexed citations

Winner, Paul, Uwe Reuter, David W. Dodick, et al.. (2018). Erenumab Safety Among Migraine Patients Using Triptans or With Cardiovascular (CV) Risk Factors (P4.100). Neurology. 90(15_supplement). 1 indexed citations

10.

Schwedt, Todd J., Uwe Reuter, Stewart J. Tepper, et al.. (2018). Early onset of efficacy with erenumab in patients with episodic and chronic migraine. The Journal of Headache and Pain. 19(1). 92–92. 72 indexed citations

11.

Goadsby, Peter J., Koen Paemeleire, Gregor Broessner, et al.. (2017). Efficacy of erenumab in subjects with episodic migraine with prior preventive treatment failure(s). Ghent University Academic Bibliography (Ghent University). 8 indexed citations

12.

Schacht, Alexander, Philip Gorwood, Philip Boyce, Ayal Schaffer, & Hernàn Picard. (2014). Depression symptom clusters and their predictive value for treatment outcomes: Results from an individual patient data meta-analysis of duloxetine trials. Journal of Psychiatric Research. 53. 54–61. 15 indexed citations

13.

Vinckier, Fabien, Laurent Cohen, Catherine Oppenheim, et al.. (2013). Reading impairment in schizophrenia: Dysconnectivity within the visual system. Neuropsychologia. 53. 187–196. 14 indexed citations

14.

Romera, Irene, Víctor Pérez, José M. Menchón, et al.. (2012). Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: A double-blind randomized study. Journal of Affective Disorders. 143(1-3). 47–55. 19 indexed citations

15.

Picard, Hernàn, et al.. (2012). A step toward an objective quantification of subtle neurological signs in schizophrenia. Psychiatry Research. 198(2). 230–234. 7 indexed citations

16.

Picard, Hernàn, et al.. (2012). Impaired saccadic adaptation in schizophrenic patients with high neurological soft sign scores. Psychiatry Research. 199(1). 12–18. 12 indexed citations

17.

Dantchev, N., et al.. (2012). Résultats de la cohorte française de l’étude observationnelle européenne FINDER : qualité de vie de patients traités par antidépresseurs. L Encéphale. 39(2). 101–108.

18.

Gourion, D., et al.. (2011). Changer d’antidépresseur : quand, comment, pourquoi ?. L Encéphale. 37. S50–S57. 2 indexed citations

19.

Picard, Hernàn, Isabelle Amado, Marie‐Chantal Bourdel, et al.. (2009). Correlates between neurological soft signs and saccadic parameters in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 33(4). 676–681. 13 indexed citations

20.

Picard, Hernàn, I. Amado, Sabine Mouchet-Mages, J.-P. Olié, & Marie‐Odile Krebs. (2007). The Role of the Cerebellum in Schizophrenia: an Update of Clinical, Cognitive, and Functional Evidences. Schizophrenia Bulletin. 34(1). 155–172. 217 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact